Penumbra Inc is a medical technology company that specializes in the development and manufacturing of innovative devices for the treatment of various vascular and neurological conditions. The company focuses on creating solutions that are minimally invasive and designed to improve patient outcomes in areas such as stroke intervention, peripheral artery disease, and other critical health challenges. Penumbra leverages advanced engineering and regulatory expertise to offer state-of-the-art products that enhance the capabilities of healthcare professionals and provide better care for patients. Read More
Shares of medical device company Penumbra (NYSE:PEN)
jumped 12.1% in the afternoon session after the company agreed to be acquired by Boston Scientific in a deal valued at approximately $14.5 billion.
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock is fair to Penumbra shareholders.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 11.1%.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 9.8% return has trailed the S&P 500 by 7.3 percentage points.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 17.2% in the morning session after it reported third-quarter 2025 financial results that surpassed Wall Street's expectations for both revenue and profit. The company's revenue grew 17.8% year on year to $354.7 million, comfortably beating analysts' consensus estimate of $340.4 million. Its profitability also showed significant improvement, with non-GAAP earnings per share (EPS) of $0.97, which was 5.3% ahead of expectations. Penumbra demonstrated increased efficiency as its operating margin expanded to 13.8%, a notable increase from 11.7% in the same quarter of the previous year. This strong all-around performance, which showcased healthy demand and enhanced profitability, prompted a positive investor reaction.
Medical device company Penumbra (NYSE:PEN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 17.8% year on year to $354.7 million. Its non-GAAP profit of $0.97 per share was 5.3% above analysts’ consensus estimates.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
